Role of Endocrine Disruptors in Thyroid Cancer

NCT ID: NCT05747365

Last Updated: 2024-04-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

222 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-07-12

Study Completion Date

2025-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

the relationship between human exposure to EDCS and TC is poorly investigated and still unclear. The aim of this study is to evaluate the possible role of old and new generation endocrine disruptors in thyroid cancer. The primary aim is to evaluate the difference in the average levels of the main endocrine disruptors (PFAS, including: PFOA, PFOS, PFDA, PFUnA, PFHpS and possibly subsequently other categories, such as bisphenols, phthalates, parabens, PCBs, flame retardants) between patients with and without a diagnosis of thyroid cancer through highly sensitive, selective and precise mass spectrometry methods, such as liquid chromatography combined with tandem mass spectrometry (LC-MS / MS).

The secondary aim is to evaluate the relationship between the concentrations of endocrine disruptors and some anamnestic variables studied (for example the type of diet, the use of personal care products).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Endocrine Disruptor Chemicals Thyroid Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Case group

Patients with thyroid cancer diagnosis within 5 years before study enrollment

Blood and urine diagnostic evaluation

Intervention Type DIAGNOSTIC_TEST

Blood and urine samples will be obtained from both case and control groups in order to evaluate EDCs concentrations

Control group

Patients without clinical diagnosis of thyroid disease

Blood and urine diagnostic evaluation

Intervention Type DIAGNOSTIC_TEST

Blood and urine samples will be obtained from both case and control groups in order to evaluate EDCs concentrations

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Blood and urine diagnostic evaluation

Blood and urine samples will be obtained from both case and control groups in order to evaluate EDCs concentrations

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients with a diagnosis of thyroid cancer in the last 5 years (arm A)
* patients without a diagnosis of thyroid cancer will match patients included in arm A

Exclusion Criteria

* subjects under 18 years old
* patients unable to sign the informed consent or questionnaires
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Istituto Auxologico Italiano

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Istituto Auxologico Italiano, IRCCS

Milan, , Italy

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Italy

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Laura Fugazzola, MD

Role: CONTACT

+390261911 ext. 2727

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Laura Fugazzola, MD

Role: primary

+390261911 ext. 2727

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

05C214

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Thyroid Hormone for Thyroid Cancer
NCT06647602 NOT_YET_RECRUITING